These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 11313792

  • 1. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
    Nyhus JK, Wolford C, Feng L, Barbera-Guillem E.
    Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
    [Abstract] [Full Text] [Related]

  • 2. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE, Shanahan F, O'Connell J, Houston AM.
    Cancer Res; 2005 Nov 01; 65(21):9817-23. PubMed ID: 16267003
    [Abstract] [Full Text] [Related]

  • 3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A.
    J Immunol; 1999 Jun 15; 162(12):7350-7. PubMed ID: 10358186
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).
    Drozdzik M, Qian C, Lasarte JJ, Bilbao R, Prieto J.
    Gene Ther; 1998 Dec 15; 5(12):1622-30. PubMed ID: 10023441
    [Abstract] [Full Text] [Related]

  • 5. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ, Canfield SE, Yan Y, Hassen W, Selleck WA, Chen SH.
    Gene Ther; 2002 Apr 15; 9(8):511-7. PubMed ID: 11948376
    [Abstract] [Full Text] [Related]

  • 6. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
    Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A.
    Eur J Immunol; 1995 Aug 15; 25(8):2253-8. PubMed ID: 7545115
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y, O-Wang J, Seimiya M, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M.
    Anticancer Res; 2002 Aug 15; 22(2A):831-6. PubMed ID: 12014659
    [Abstract] [Full Text] [Related]

  • 8. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M.
    Int J Mol Med; 2002 Mar 15; 9(3):281-5. PubMed ID: 11836634
    [Abstract] [Full Text] [Related]

  • 9. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y, O-Wang J, Wada A, Takiguchi Y, Tatsumi K, Kuriyama T, Sakiyama S, Tagawa M.
    Cancer Gene Ther; 2003 Feb 15; 10(2):134-40. PubMed ID: 12536202
    [Abstract] [Full Text] [Related]

  • 10. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
    Lee SH, Bar-Haim E, Goldberger O, Reich-Zeliger S, Vadai E, Tzehoval E, Eisenbach L.
    Immunol Lett; 2004 Feb 15; 91(2-3):119-26. PubMed ID: 15019279
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
    Imai T, Adachi S, Nishijo K, Ohgushi M, Okada M, Yasumi T, Watanabe K, Nishikomori R, Nakayama T, Yonehara S, Toguchida J, Nakahata T.
    Oncogene; 2003 Dec 18; 22(58):9231-42. PubMed ID: 14647441
    [Abstract] [Full Text] [Related]

  • 13. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
    Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I.
    Cancer Res; 2001 Jan 15; 61(2):577-81. PubMed ID: 11212252
    [Abstract] [Full Text] [Related]

  • 14. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R, Emi M, Tanabe K, Uchida Y, Toge T.
    Cancer; 2004 Jun 01; 100(11):2281-91. PubMed ID: 15160330
    [Abstract] [Full Text] [Related]

  • 15. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
    Cheng WF, Lee CN, Chang MC, Su YN, Chen CA, Hsieh CY.
    Mol Ther; 2005 Nov 01; 12(5):960-8. PubMed ID: 15979942
    [Abstract] [Full Text] [Related]

  • 16. Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering RNA targeting KITENIN, a metastasis-enhancing protein.
    Lee JH, Cho ES, Kim MY, Seo YW, Kho DH, Chung IJ, Kook H, Kim NS, Ahn KY, Kim KK.
    Cancer Res; 2005 Oct 01; 65(19):8993-9003. PubMed ID: 16204073
    [Abstract] [Full Text] [Related]

  • 17. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M.
    Int Immunopharmacol; 2005 Feb 01; 5(2):281-8. PubMed ID: 15652759
    [Abstract] [Full Text] [Related]

  • 18. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
    Satchell AC, Barnetson RS, Halliday GM.
    Br J Dermatol; 2004 Jul 01; 151(1):42-9. PubMed ID: 15270871
    [Abstract] [Full Text] [Related]

  • 19. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A, Tada Y, Kawamura K, Takiguchi Y, Tatsumi K, Kuriyama T, Takenouchi T, O-Wang J, Tagawa M.
    Cancer Gene Ther; 2007 Mar 01; 14(3):262-7. PubMed ID: 17053813
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.